Showing 21-30 of 135 results for "".
Emerging Insights into the Immunologic Subtypes of Atopic Dermatitis in Children
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/derm-hub/37157/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, discusses new understandings regarding the immunologic subtypes of atopic dermatitis and how they should influence treatment selection.Make The Experience Unforgettable
https://practicaldermatology.com/topics/practice-management/make-the-experience-unforgettable/18583/When practices looking for ways to differentiate should focus on creating amazing experiences, says Robert Rullo. One important consideration is the person answering your phones, who needs to convey your expertise and your story.Advances in Wound Care
https://practicaldermatology.com/conferences/maui-derm-2022/maui-derm-2022-video/20040/Robert S. Kirsner, MD, PhD discusses the latest in wound healing science and resulting changes in how leading wound care experts are approaching patient care. From innovative products to greater understanding of the science, there are many options to help patients heal.Therapeutic Approaches in Pediatric Atopic Dermatitis
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/derm-hub/37158/Robert Sidbury, MD, MPH, Chief of Dermatology at Seattle Children’s Hospital and Professor in the University of Washington Department of Pediatrics, explains how to adjust a therapeutic approach to pediatric atopic dermatitis, particularly when considering long-term use of topical steroids or calcinPhio Pharmaceuticals Takes Aim at Skin Cancer
https://practicaldermatology.com/series/c-suite-chats/phio-pharmaceuticals-takes-aim-skin-cancer/24316/In the first episode of Practical Dermatology's C-Suite Chats, Robert Bitterman, CEO of Phio Pharmaceuticals, discusses the company's patented INTASYL technology. Learn more about this platform for creating and delivering uniquely modified siRNA compounds to treat cancer.DermWireTV: Skyrizi for PsA; Toxins and Wound Healing at Maui Derm; SDDS Registration
https://practicaldermatology.com/topics/psoriasis/skyrizi-for-psa-toxins-and-wound-healing-at-maui-derm-sdds-registration-dermwiretv/20057/Skyrizi (AbbVie) is now approved for the treatment of adults with active psoriatic arthritis. Michael Gold, MD was among the speakers who offered updates on cosmetic trends as well as medical care at Maui Dermatology for Dermatologists last week. He spoke about high-dose neurotoxins. Robert KirsnerNew in My Practice: OTC
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/new-in-my-practice-otc-3/23492/Hair’s the Thing
https://practicaldermatology.com/topics/hair-nails/hairs-the-thing/23909/Dermatologists can take a more proactive role in caring for patients with alopecia.Currents: Think Big
https://practicaldermatology.com/topics/skin-cancer-photoprotection/currents-think-big/20893/Big picture approaches can unlock new solutions to dermatologic diseases.AbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society an